Search Results - "Garon, Edward B."

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial by Shaverdian, Narek, MD, Lisberg, Aaron E, MD, Bornazyan, Krikor, MD, Veruttipong, Darlene, MPH, Goldman, Jonathan W, MD, Formenti, Silvia C, MD, Garon, Edward B, MD, Lee, Percy, Dr

“…Summary Background Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity…”
Get full text

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer by Gadgeel, Shirish, Rodríguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Dómine, Manuel, Hui, Rina, Hochmair, Maximilian J, Clingan, Philip, Powell, Steven F, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Garon, Edward B, Novello, Silvia, Rubio-Viqueira, Belén, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E, Yang, Jing, Bas, Tuba, Pietanza, M Catherine, Garassino, Marina C

“…In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared…”
Get full text

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer by Rizvi, Naiyer A., Hellmann, Matthew D., Snyder, Alexandra, Kvistborg, Pia, Makarov, Vladimir, Havel, Jonathan J., Lee, William, Yuan, Jianda, Wong, Phillip, Ho, Teresa S., Miller, Martin L., Rekhtman, Natasha, Moreira, Andre L., Ibrahim, Fawzia, Bruggeman, Cameron, Gasmi, Billel, Zappasodi, Roberta, Maeda, Yuka, Sander, Chris, Garon, Edward B., Merghoub, Taha, Wolchok, Jedd D., Schumacher, Ton N., Chan, Timothy A.

“…Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants…”
Get full text

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370) by Spigel, David R, Reynolds, Craig, Waterhouse, David, Garon, Edward B, Chandler, Jason, Babu, Sunil, Thurmes, Paul, Spira, Alexander, Jotte, Robert, Zhu, Jin, Lin, Wen Hong, Blumenschein, Jr, George

“…Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is a first-line treatment for ALK translocation-positive advanced non-small cell lung cancer…”
Get more information

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial by Herbst, Roy S, Prof, Baas, Paul, Prof, Kim, Dong-Wan, MD, Felip, Enriqueta, MD, Pérez-Gracia, José L, MD, Han, Ji-Youn, Prof, Molina, Julian, MD, Kim, Joo-Hang, Prof, Arvis, Catherine Dubos, MD, Ahn, Myung-Ju, Prof, Majem, Margarita, MD, Fidler, Mary J, MD, de Castro, Gilberto, MD, Garrido, Marcelo, MD, Lubiniecki, Gregory M, MD, Shentu, Yue, PhD, Im, Ellie, MD, Dolled-Filhart, Marisa, PhD, Garon, Edward B, MD

“…Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for…”
Get full text

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance by Turner, David C, Kondic, Anna G, Anderson, Keaven M, Robinson, Andrew G, Garon, Edward B, Riess, Jonathan Wesley, Jain, Lokesh, Mayawala, Kapil, Kang, Jiannan, Ebbinghaus, Scot W, Sinha, Vikram, de Alwis, Dinesh P, Stone, Julie A

“…To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non-small cell lung…”
Get full text

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 by Waterhouse, David M, Garon, Edward B, Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B, Keogh, George, Creelan, Ben, Einhorn, Lawrence H, Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B, Reynolds, Craig, Blumenschein, Jr, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R

“…Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial by Garon, Edward B, Dr, Ciuleanu, Tudor-Eliade, Prof, Arrieta, Oscar, MD, Prabhash, Kumar, Prof, Syrigos, Konstantinos N, Prof, Goksel, Tuncay, Prof, Park, Keunchil, Prof, Gorbunova, Vera, MD, Kowalyszyn, Ruben Dario, MD, Pikiel, Joanna, MD, Czyzewicz, Grzegorz, MD, Orlov, Sergey V, Prof, Lewanski, Conrad R, MD, Thomas, Michael, Prof, Bidoli, Paolo, MD, Dakhil, Shaker, MD, Gans, Steven, MD, Kim, Joo-Hang, Prof, Grigorescu, Alexandru, Prof, Karaseva, Nina, MD, Reck, Martin, MD, Cappuzzo, Federico, MD, Alexandris, Ekaterine, MS, Sashegyi, Andreas, PhD, Yurasov, Sergey, MD, Pérol, Maurice, MD

“…Summary Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of…”
Get full text

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations by Remon, Jordi, Passiglia, Francesco, Ahn, Myung-Ju, Barlesi, Fabrice, Forde, Patrick M, Garon, Edward B, Gettinger, Scott, Goldberg, Sarah B, Herbst, Roy S, Horn, Leora, Kubota, Kaoru, Lu, Shun, Mezquita, Laura, Paz-Ares, Luis, Popat, Sanjay, Schalper, Kurt A, Skoulidis, Ferdinandos, Reck, Martin, Adjei, Alex A, Scagliotti, Giorgio V

“…In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class…”
Get more information

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement by Sears, Catherine R, Peikert, Tobias, Possick, Jennifer D, Naidoo, Jarushka, Nishino, Mizuki, Patel, Sandip P, Camus, Philippe, Gaga, Mina, Garon, Edward B, Gould, Michael K, Limper, Andrew H, Montgrain, Philippe R, Travis, William D, Rivera, M Patricia

“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening…”
Get full text

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer by Dhar, Manjima, Wong, Jessica, Che, James, Matsumoto, Melissa, Grogan, Tristan, Elashoff, David, Garon, Edward B., Goldman, Jonathan W., Sollier Christen, Elodie, Di Carlo, Dino, Kulkarni, Rajan P.

“…Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells,…”
Get full text

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer by PATEL, Jyoti D, SOCINSKI, Mark A, GUBA, Susan C, JINGYI LIU, FRIMODT-MOLLER, Bente, JOHN, William J, OBASAJU, Coleman K, PENNELLA, Eduardo J, BONOMI, Philip, GOVINDAN, Ramaswamy, GARON, Edward B, REYNOLDS, Craig H, SPIGEL, David R, OLSEN, Mark R, HERMANN, Robert C, JOTTE, Robert M, BECK, Thaddeus, RICHARDS, Donald A

“…PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of…”
Get full text

Proteomic Analysis of Human Saliva From Lung Cancer Patients Using Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry by Xiao, Hua, Zhang, Lei, Zhou, Hui, Lee, Jay M., Garon, Edward B., Wong, David T.W.

“…Lung cancer is often asymptomatic or causes only nonspecific symptoms in its early stages. Early detection represents one of the most promising approaches to…”
Get full text

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium by Steuer, Conor E., Behera, Madhusmita, Berry, Lynne, Kim, Sungjin, Rossi, Michael, Sica, Gabriel, Owonikoko, Taofeek K., Johnson, Bruce E., Kris, Mark G., Bunn, Paul A., Khuri, Fadlo R., Garon, Edward B., Ramalingam, Suresh S.

“…BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities…”
Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) by Brahmer, Julie R, Govindan, Ramaswamy, Anders, Robert A, Antonia, Scott J, Sagorsky, Sarah, Davies, Marianne J, Dubinett, Steven M, Ferris, Andrea, Gandhi, Leena, Garon, Edward B, Hellmann, Matthew D, Hirsch, Fred R, Malik, Shakuntala, Neal, Joel W, Papadimitrakopoulou, Vassiliki A, Rimm, David L, Schwartz, Lawrence H, Sepesi, Boris, Yeap, Beow Yong, Rizvi, Naiyer A, Herbst, Roy S

“…Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until…”
Get full text

Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis by Li, Shuo, Noor, Zorawar S., Zeng, Weihua, Stackpole, Mary L., Ni, Xiaohui, Zhou, Yonggang, Yuan, Zuyang, Wong, Wing Hung, Agopian, Vatche G., Dubinett, Steven M., Alber, Frank, Li, Wenyuan, Garon, Edward B., Zhou, Xianghong Jasmine

“…Cell-free DNA (cfDNA) is attractive for many applications, including detecting cancer, identifying the tissue of origin, and monitoring. A fundamental task…”
Get full text

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review by Garon, Edward B, Visseren-Grul, Carla, Rizzo, Maria Teresa, Puri, Tarun, Chenji, Suresh, Reck, Martin

“…In the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall…”
Get full text

Development of transcriptomic biomarker signature in human saliva to detect lung cancer by Zhang, Lei, Xiao, Hua, Zhou, Hui, Santiago, Silverio, Lee, Jay M., Garon, Edward B., Yang, Jieping, Brinkmann, Ole, Yan, Xinmin, Akin, David, Chia, David, Elashoff, David, Park, No-Hee, Wong, David T. W.

“…Lung cancer is the leading cause of cancer death for both men and women worldwide. Since most of the symptoms found for lung cancer are nonspecific, diagnosis…”
Get full text

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer by Garon, Edward B, Chih-Hsin Yang, James, Dubinett, Steven M

“…Chronic inflammation is associated with an increased risk of several diseases, including cancer. A complex tumor microenvironment created and maintained by a…”
Get full text